This article highlights the challenges and proposes strategies regarding the predominantly off-label use of medical devices for congenital cardiac lesions in the cath lab.
Answers are grounded in this paper and cite their sources.
Off-label device use predominates in congenital cath lab procedures; leaves open needs for dedicated trials and postmarket surveillance.
The majority of devices used to treat congenital cardiac lesions in the cardiac catheterization laboratory are used on an off-label basis. This article discusses the predicaments faced by the interventional cardiologist when implanting devices on an off-label basis, using procedural examples of PFO closure and endovascular stent placement. Strategies that may benefit patient and provider, as well as satisfying regulatory agencies are suggested.
No takes yet. Share an insight, caveat, or question.
Holzer et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: